Phillip Minar

BACKGROUND: Our team (Xiong et al. 2021) recently developed an infliximab population pharmacokinetic (popPK) model in children and young adults with Crohn’s disease (CD). We found that prediction accuracy improved when all five covariates of drug clearance were included…

BACKGROUND: Perianal fistulizing complications (PFC) of Crohn’s disease (CD) are highly morbid and difficult to treat. Despite the advent of biologic medications, antibiotics remain a mainstay of PFC treatment…

INTRODUCTION: Due to its rarity, anal adenocarcinoma (AA) does not have a standardized staging system. The tumor (T) stage of an adenocarcinoma arising from the anal canal could be based on depth of invasion, as for rectal adenocarcinoma, or on size, as in anal squamous cell carcinoma…

BACKGROUND: Given the variable response to anti-TNF therapy in patients with Crohn’s disease (CD), we hypothesized there is a core biologic (inflammatory) signature associated with early response and endoscopic healing (EH)…

BACKGROUND: Prior pharmacokinetic (PK) investigations have identified an association between anti-TNF trough concentrations (cTrough) and clinical or biochemical remission for children with Crohn’s Disease (CD)…